Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Daiichi Sankyo
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
0.1%
+0.0% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:NeutralThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
AstraZeneca
Competitor Displacement Rate
0.1%
Competitors are displacing Daiichi Sankyo in 0.1% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Daiichi Sankyo's strengths in oncology, particularly ADCs, are increasingly challenged by AstraZeneca's co-development efforts and broader market access.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[bloodjournal.org][annals.org]⚠️ Identified Vulnerability:Co-Development Synergy
Primary Threat Identified:AstraZeneca
Target Persona:Clinical Trial Investigators
🚨 Threat Velocity:6/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)